GRI Bio, Inc.

Contributing Author

Recent Articles by GRI Bio, Inc.

May-22	GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results GRI GlobeNewswire
May-21	GRI Bio to Participate in the Virtual Investor Closing Bell Series GRI GlobeNewswire
May-16	GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase GRI GlobeNewswire
May-15	GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 GRI GlobeNewswire
May-08	GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire
May-07	GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") GRI GlobeNewswire